Flower lose, a cell fitness marker, predicts COVID‐19 prognosis

Authors:

Abstract
Risk stratification of COVID‐19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe‐Lose , can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe‐Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID‐19 patients. We performed a post‐mortem examination of infected lung tissue in deceased COVID‐19 patients to determine hFwe‐Lose’ s biological role in acute lung injury. We then performed an observational study ( n = 283) to evaluate whether hFwe‐Lose expression (in nasopharyngeal samples) could accurately predict hospitalization or death in COVID‐19 patients. In COVID‐19 patients with acute lung injury, hFwe‐Lose is highly expressed in the lower respiratory tract and is co‐localized to areas of cell death. In patients presenting in the early phase of COVID‐19 illness, hFwe‐Lose expression accurately predicts subsequent hospitalization or death with positive predictive values of 87.8–100% and a negative predictive value of 64.1–93.2%. hFwe‐Lose outperforms conventional inflammatory biomarkers and patient age and comorbidities, with an area under the receiver operating characteristic curve (AUROC) 0.93–0.97 in predicting hospitalization/death. Specifically, this is significantly higher than the prognostic value of combining biomarkers (serum ferritin, D‐dimer, C‐reactive protein, and neutrophil–lymphocyte ratio), patient age and comorbidities (AUROC of 0.67–0.92). The cell fitness marker, hFwe‐Lose , accurately predicts outcomes in COVID‐19 patients. This finding demonstrates how tissue fitness pathways dictate the response to infection and disease and their utility in managing the current COVID‐19 pandemic.
Funding Information
  • Swiss Cancer League
  • Seeds of Science, UAMS
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Fundação para a Ciência e a Tecnologia
  • Fundamental Mandates
  • ERC
  • Josef Steiner Cancer Research Foundation
  • Fundação Champalimaud
  • Novo Nordisk Fonden (NNF17CC0027852)
  • Lundbeck Foundation (R313–2019–421)
  • la Caixa (LCF/BQ/PR20/11770006)
  • FIS (Ministry of Health), Madrid, Spain (PI17/01981)
  • DFG Clinical Research Unit (KFO 309)
  • Deutsches Zentrum für Lungenforschung
  • DFG Collaborative Research Center (SFB1021)
  • Deutsche Forschungsgemeinschaft (KFO309 TP08)
  • Botnar Research Centre for Child Health, University of Basel (FTC‐2020‐10)
  • Thelma Newmeyer Corman Chair in Cancer Research
  • VCU Commercialization Fund
  • NIH/NCI (R01 CA259599)
  • Fundação para a Ciência e a Tecnologia (2020.05319.BD)
  • Fundação para a Ciência e a Tecnologia (SFRH/BD/139138/2018)
  • Fundação para a Ciência e a Tecnologia (BD/135367/2017)
  • NIH/NIGMS (P20GM121322)
  • NIH/NIGMS (2U54 GM104942‐03)
  • NIH/NIGMS (P20GM103434)
  • National Science Foundation (NSF/1920920)
  • National Science Foundation (NSF/1761792)
  • Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
  • National Institutes of Health (P50 SPORE CA228991)
  • Honorable Tina Brozman Foundation

This publication has 49 references indexed in Scilit: